UNSPSC 51314382: Chlorpheniramine/dextromethorphan/guaifenesin/phenylephrine/sodium salicylate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE504. This VA Drug Class (RE504) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE/EXPECTORANT.

UNSPSC 51314382 Chlorpheniramine/dextromethorphan/guaifenesin/phenylephrine/sodium salicylate is a Commodity code that, based on recent state and local activity, does not align with the products actually being procured under it. The single recent opportunity on record—Seminole County, Florida's solicitation for Naloxone and Safe Drug Deactivation Systems—bears no relationship to the over-the-counter cold and allergy medication combination the code nominally describes. State and local procurement offices appear to be tagging unrelated health-related products and services to this code, creating a mismatch between the taxonomy and actual purchasing activity.

Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The procurement was a competitive IFB with a response deadline of July 26, 2023, and required vendors to include all shipping and delivery costs in their bids. The contract, potentially funded through FEMA, carried a two-year initial term with a one-year renewal option, a three-month probationary period, and standard compliance requirements including drug-free workplace certification, E-Verify authorization, and workers' compensation and general liability insurance. The code shows minimal recent activity and little evidence of use for its stated pharmaceutical scope in state and local procurement.